Drug
Samalizumab
Samalizumab: highest development phase Phase 2/3, developed by Aveo Pharmaceuticals. 1 trial record tracked on RxWires.
- Highest phase
- Phase 2/3
- Developer
- Aveo Pharmaceuticals
Trials
| Drug | Phase | Indication |
|---|---|---|
| Samalizumab (BAML-16-001-S1) NCT03013998 | Phase 2/3 | Previously Untreated Relapsed Refractory Acute Myeloid Leukemia |
Latest
No recent events.
Follow Samalizumab on RxWires to get trial status changes, FDA actions, filings and patent dates as they happen.
Sourced from ClinicalTrials.gov, openFDA, SEC EDGAR and the FDA Orange Book. Not investment or medical advice.